BridgeMD
New treatment option for Prostate Cancer
Official title Early Detection of Prostate Cancer
ClinicalTrials.gov ID: NCT04556916
What this study is testing
- What it's testing
- This study is the early detection of prostate cancer by analysing circulating bloodbased biomarkers. Based on our latest developments, we primarily aim to assess the validity of CTCs (circulating tumour cells) and tumour cell products circulating in blood (DNA, exosomes) for early PCa (Prostate cancer) detection.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older, men only
You may be able to join if
- Patient :
- Men over 40 being suspicious of prostate cancer
- Subject with PSA ≥ 4 and designated for biopsy
- people must be able to attend all scheduled visits and to comply with all trial procedures
- mpMRI done before prostate biopsy
You likely can't join if
- Patient :
- Subject with histologically confirmed prostate cancer
- Subject with a verified viral infection (HIV or Hepatitis)
- Subject under Finasteride treatment
- Subject under hormonal treatment (analogs, antagonists, androgenics)
- Subject with other cancer diagnosed
See the full eligibility criteria
- Patient :
- Men over 40 being suspicious of prostate cancer
- Subject with PSA ≥ 4 and designated for biopsy
- people must be able to attend all scheduled visits and to comply with all trial procedures
- mpMRI done before prostate biopsy
- Subject must be covered by public health insurance
- Signed informed consent form Subject Control Patient patient free from prostatic disease :
- Men over 40 with no suspicion of prostate cancer
- Subject with PSA \< 2.5 and normal digital rectal examination
- Subject must be covered by public health insurance
- Signed informed consent form
- Patient :
- Subject with histologically confirmed prostate cancer
- Subject with a verified viral infection (HIV or Hepatitis)
- Subject under Finasteride treatment
- Subject under hormonal treatment (analogs, antagonists, androgenics)
- Subject with other cancer diagnosed
- Subject unable to sign consent
- Planned longer stay outside the region that prevents compliance with the visit plan
- Subject deprived of liberty, protected adults or vulnerable persons
- Urinary infection ≤ 2 months
- Subject excluding health insurance registration
- Subject refusing to perform prostate biopsy
- Subject who are in a dependency or employment with the sponsor or the investigator Exclusion Criteria Subject Control :
- Subject with histologically confirmed prostate cancer
- Subject with a verified viral infection (HIV or Hepatitis)
- Subject under Finasteride treatment
- Subject with other cancer diagnosed
- Subject unable to sign consent
- Planned longer stay outside the region that prevents compliance with the visit plan
- Subject deprived of liberty, protected adults or vulnerable persons
- Urinary infection ≤ 2 months
- Subject excluding health insurance registration
The study team makes the final eligibility decision.
Where it's taking place
- Montpellier, France
- Nîmes, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montpellier, France; Nîmes, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.